Becton Dickinsn receives Investment Bank Analyst Rating Update
BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new...
Investing.com - Becton Dickinson (NYSE: BDX) reported second quarter EPS of $2.86, $0.12 better than the analyst estimate of $2.74. Revenue for the quarter came in at $4.8B versus...
September has meant increased volatility and doldrums in the broader markets. For instance, so far this month, the Dow Jones Industrial Average, the S&P 500 and the NASDAQ 100...
The stock market finished August with its fifth monthly gain as one of the strongest rallies since 2000 continued pushing higher. Indeed, this rally looks like it has enough...
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
|Average||286.39 (+13.87% Upside)|
|No. of Analysts||18|
|Moving Averages||Sell||Buy||Buy||Strong Buy||Strong Buy|
|Technical Indicators||Strong Sell||Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Sell||Buy||Strong Buy||Strong Buy||Strong Buy|